<!DOCTYPE html>
<html lang="en">
<head>
  
  
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    
    
    <link rel="canonical" href="https://jzpero.github.io/mednotes/Critical%20Care/ARDS/ECLS%20for%20ARDS/">
    <link rel="shortcut icon" href="../../../img/favicon.ico">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=0" />
    <title>ECLS for ARDS/Acute Respiratory Failure - MedNotes</title>
    <link href="../../../css/bootstrap-3.3.7.min.css" rel="stylesheet">
    <link href="../../../css/font-awesome-4.7.0.css" rel="stylesheet">
    <link href="../../../css/base.css" rel="stylesheet">
    <link rel="stylesheet" href="../../../css/highlight.css">
    <!-- HTML5 shim and Respond.js IE8 support of HTML5 elements and media queries -->
    <!--[if lt IE 9]>
        <script src="https://oss.maxcdn.com/libs/html5shiv/3.7.0/html5shiv.js"></script>
        <script src="https://oss.maxcdn.com/libs/respond.js/1.3.0/respond.min.js"></script>
    <![endif]-->

    <script src="../../../js/jquery-3.2.1.min.js"></script>
    <script src="../../../js/bootstrap-3.3.7.min.js"></script>
    <script src="../../../js/highlight.pack.js"></script>
    
    <base target="_top">
    <script>
      var base_url = '../../..';
      var is_top_frame = false;
        
        var pageToc = [
          {title: "ECLS for ARDS/Acute Respiratory Failure", url: "#_top", children: [
          ]},
          {title: "ECLS Background", url: "#ecls-background", children: [
              {title: "ECMO Centres", url: "#ecmo-centres" },
              {title: "Major Complications of ECMO", url: "#major-complications-of-ecmo" },
          ]},
          {title: "Clinical Use for ARDS", url: "#clinical-use-for-ards", children: [
          ]},
          {title: "Evidence - VV-ECMO", url: "#evidence-vv-ecmo", children: [
          ]},
          {title: "Evidence for ECCO2R", url: "#evidence-for-ecco2r", children: [
          ]},
          {title: "References", url: "#references", children: [
          ]},
        ];

    </script>
    <script src="../../../js/base.js"></script> 
</head>

<body>
<script>
if (is_top_frame) { $('body').addClass('wm-top-page'); }
</script>



<div class="container-fluid wm-page-content">
  <a name="_top"></a>
    

    
    
      
    

  <div class="row wm-article-nav-buttons" role="navigation" aria-label="navigation">
    
    <div class="wm-article-nav pull-right">
      <a href="../Proning%20in%20ARDS/" class="btn btn-xs btn-default pull-right">
        Next
        <i class="fa fa-chevron-right" aria-hidden="true"></i>
      </a>
      <a href="../Proning%20in%20ARDS/" class="btn btn-xs btn-link">
        Proning in ARDS
      </a>
    </div>
    
    <div class="wm-article-nav">
      <a href="../Acute%20Respiratory%20Distress%20Syndrome/" class="btn btn-xs btn-default pull-left">
        <i class="fa fa-chevron-left" aria-hidden="true"></i>
        Previous</a><a href="../Acute%20Respiratory%20Distress%20Syndrome/" class="btn btn-xs btn-link">
        ARDS
      </a>
    </div>
    
  </div>

    

    <h1 id="ecls-for-ardsacute-respiratory-failure">ECLS for ARDS/Acute Respiratory Failure</h1>
<p>There is a subset of patients for whom conservative medical management is not enough to support the patient in severe <a href="../Acute%20Respiratory%20Distress%20Syndrome/">ARDS</a>. ECMO/ECLS can partially or fully bypass the lungs to support gas exchange and facilitate lung-protective ventilation. Interestingly, ECLS may promote "ultra-lung-protective" ventilation by mitigating VILI and facilitating even further reductions in mechanical ventilation intensity.</p>
<h1 id="ecls-background">ECLS Background</h1>
<p>See <a href="ECLS">ECLS</a>. Essentially, can be either ECMO or ECCO2-R. ECMO can be wither venovenous (VV-ECMO) or veno-arterial (VA-ECMO) if cardiac support is required.
- oxygenation is blood flow rate dependent
- CO2 clearance is gas flow rate dependent (i.e. "sweep flow")</p>
<h2 id="ecmo-centres">ECMO Centres</h2>
<ul>
<li>centres with &gt;30 cases per year have lower mortality than lower-volume (&lt;6 cases yearly)</li>
</ul>
<h2 id="major-complications-of-ecmo">Major Complications of ECMO</h2>
<ul>
<li>bleeding (major cause of M&amp;M)<ul>
<li>most common sites: cannulation site, GI, lung, CNS</li>
<li>23% rate of bleeding complications in VV ECMO</li>
</ul>
</li>
<li>thrombosis<ul>
<li>occurs in 25% of patients</li>
</ul>
</li>
<li>mechanical complications of the cannular or circuit<ul>
<li>includes cannulation site bleeding, vascular injury, DVT, limb ischemia, air embolism, circuit failure from clot accumulation on the membrane lung</li>
</ul>
</li>
<li>Neurologic complications occur in 10% of patients - ischemic and hemorrhagic stroke are the most common</li>
</ul>
<h1 id="clinical-use-for-ards">Clinical Use for ARDS</h1>
<ul>
<li>NO role for routine ECCO2R in ARDS</li>
<li>VV-ECMO has now shifted from being reserved for patients as a salvage therapy to prevent death from refractory gas exchange to and early adjunct to lung-protective ventilation in patients with severe ARDS when conventional evidence-based strategies (fluid balance, proning, <a href="../../Procedures/Neuromuscular%20Blockade/">neuromuscular blockade</a>, steroids) are failing<ul>
<li>due to costs/risks, ECMO has to be selected well for the right patient. </li>
<li>Poorer outcomes are associated with older age, immunocompromised status, number of failing organs, duration of pre-ECMO IMV, and severity of impairment in lung compliance</li>
<li><em>paucity of long-term data</em> in patients receiving ECMO<ul>
<li>CESAR: 6-month QOL same or better compared to CMV</li>
</ul>
</li>
</ul>
</li>
</ul>
<p><img alt="" src="../_attachments/Pasted%20image%2020221219155805.png" /></p>
<h1 id="evidence-vv-ecmo">Evidence - VV-ECMO</h1>
<p>The <strong>CESAR (2009)</strong> trial was a landmark trial that looked at the application of modern VV-ECMO in patients with severe and potentially reversible respiratory failure refractory to conventional management.</p>
<ul>
<li>Intervention: transfer to ECMO centre for ECMO consideration</li>
<li>Control: management of respiratory failure without ECMO</li>
<li>Results: 63% survival without death or severe disability at 6 months vs 47%<ul>
<li>only 75% of those transferred received ECMO (bias towards null)</li>
<li>NNT 6 for primary outcome</li>
</ul>
</li>
<li>limitations<ul>
<li>lack of mandated lung protective ventilation in control group (70% only) compared to intervention group (93%) -- bias towards positive</li>
</ul>
</li>
</ul>
<p>The <strong>2009 H1N1 pandemic</strong> provided anecdotal observational data that suggested improved survival rates in patients with severe viral-related ARDS.</p>
<p>The <strong>EOLIA (2018)</strong> multicentre trial randomly assigned patients with very severe ARDS to immediate VV-ECMO within 7 days of mechanical ventilation or conventional mechanical ventilation alone.</p>
<ul>
<li>Investigators were also encouraged to use <a href="../../Procedures/Neuromuscular%20Blockade/">NMB</a> and prone positioning <em>prior</em> to randomization.</li>
<li>Very severe ARDS: PF &lt; 50 for 3 hours, PF/80 for 6 hours, or pH  7.25 with PaCO2 &gt; 50 for 6 hours</li>
<li>Primary outcome: 60-day mortality was lower in the ECMO group but the difference was not statistically significant (35% vs. 46%, p value 0.09)</li>
<li>Secondary outcome: <em>death or cross-over to ECMO</em> occured in 58% (control) vs 35% (intervention), P&lt;0.001<ul>
<li>cross-over group (28% of control group) had very high mortality, 57%</li>
</ul>
</li>
<li>Adverse events: similar except for greated transfusions in ECMO group</li>
</ul>
<div class="admonition note">
<p class="admonition-title">Summary of evidence for VV-ECMO in ARDS</p>
<ul>
<li>Two randomized controlled trials (<strong>CESAR</strong>, <strong>EOLIA</strong>) suggest that for severe ARDS, VV-ECMO may reduce mortality in addition to standard conventional care.</li>
<li>Baseline mortality is very high, and NNT is probably ~6-10.</li>
</ul>
</div>
<p><img alt="" src="../_attachments/Pasted%20image%2020221219154417.png" /></p>
<h1 id="evidence-for-ecco2r">Evidence for ECCO2R</h1>
<p>Traditional ARDSNet-informed lung-protective ventilation (Vt &lt; 4-8 ml/kg PBW and Pplat &lt; 30 cm H2O) may be still injurious in 1/3 of patients with severe ARDS. ECCO2R can lower the intensity of mechanical ventilation by enhancing CO2 removal, lowering mechanical ventilation requirements.</p>
<p>Three RCTs have examined ECCO2R in this setting:
1. Morris et al - no difference for ECCO2R vs CMV in 40 patients with severe ARDS
2. Xtravent-study - ECCO2R + 3 mL/kg Vt vs standard of care --&gt; no difference in 60-day VFD/death outcome
3. Protective Ventilation with Veno-venous Lung Assist in Respiratory Failure (REST) trial - ECCO2R did not improve 90-day mortality and VFD at 28 days, but did increase bleeding and <a href="../../Neuro%20Critical%20Care/Intracranial%20Hemorrhage/">ICH</a> compared to control.</p>
<h1 id="references">References</h1>
<ol>
<li>Munshi L, Brodie D, Fan E. Extracorporeal Support for Acute Respiratory Distress Syndrome in Adults. <em>NEJM Evidence</em>. 2022;1(10):EVIDra2200128. doi:<a href="https://doi.org/10.1056/EVIDra2200128">10.1056/EVIDra2200128</a></li>
<li>Peek GJ, Mugford M, Tiruvoipati R, et al. <strong>Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial.</strong> Lancet 2009; 374:1351-63.</li>
<li>Combes A, Hajage D, Capellier G et al. <strong>Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome.</strong> N Engl J Med. 2018; 378:1965-1975</li>
</ol>

  <br>
    

    
    
      
    

  <div class="row wm-article-nav-buttons" role="navigation" aria-label="navigation">
    
    <div class="wm-article-nav pull-right">
      <a href="../Proning%20in%20ARDS/" class="btn btn-xs btn-default pull-right">
        Next
        <i class="fa fa-chevron-right" aria-hidden="true"></i>
      </a>
      <a href="../Proning%20in%20ARDS/" class="btn btn-xs btn-link">
        Proning in ARDS
      </a>
    </div>
    
    <div class="wm-article-nav">
      <a href="../Acute%20Respiratory%20Distress%20Syndrome/" class="btn btn-xs btn-default pull-left">
        <i class="fa fa-chevron-left" aria-hidden="true"></i>
        Previous</a><a href="../Acute%20Respiratory%20Distress%20Syndrome/" class="btn btn-xs btn-link">
        ARDS
      </a>
    </div>
    
  </div>

    <br>
</div>

<footer class="container-fluid wm-page-content">
  <p>Documentation built with <a href="https://www.mkdocs.org/">MkDocs</a> using <a href="https://github.com/gristlabs/mkdocs-windmill">Windmill</a> theme by Grist Labs.</p>
</footer>

</body>
</html>